SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic...

Area of Science:

• Oncology
• Molecular Pathology
• Translational Research

Background:

• Recent studies identified small cell lung carcinoma (SCLC) subtypes based on RNA expression of ASCL1, NEUROD1, POU2F3, and YAP1.
• Limited data exists on the protein-level distribution of these markers and their association with pathologic features in clinical SCLC samples.

Purpose of the Study:

• To comprehensively analyze the protein expression of ASCL1, NEUROD1, POU2F3, and YAP1 in clinical SCLC samples.
• To correlate these molecular subtypes with histopathologic characteristics and established neuroendocrine markers.

Main Methods:

• Immunohistochemistry was performed on 174 SCLC patient samples to assess the expression of ASCL1, NEUROD1, POU2F3, and YAP1.
• Expression data was correlated with histologic features and markers such as synaptophysin, chromogranin A, CD56, INSM1, TTF-1, and DLL3.

Main Results:

• ASCL1 and NEUROD1 showed varied expression patterns, with 69% ASCL1-dominant and 17% NEUROD1-dominant subtypes.
• POU2F3 was expressed in 7% of cases and was mutually exclusive of ASCL1 and NEUROD1.
• ASCL1/NEUROD1 double-negative tumors, including POU2F3-positive cases, exhibited a neuroendocrine-low profile.

Conclusions:

• This study provides the first comprehensive immunohistochemical analysis of novel SCLC subtypes in patient samples.
• ASCL1/NEUROD1 double-negative tumors represent a distinct neuroendocrine-low subtype.
• Expression profiles in native samples are more heterogeneous than in experimental models, highlighting potential prognostic and therapeutic implications.